Literature DB >> 25398338

Genome editing in human stem cells.

Susan M Byrne1, Prashant Mali1, George M Church2.   

Abstract

The use of custom-engineered sequence-specific nucleases (including CRISPR/Cas9, ZFN, and TALEN) allows genetic changes in human cells to be easily made with much greater efficiency and precision than before. Engineered double-stranded DNA breaks can efficiently disrupt genes, or, with the right donor vector, engineer point mutations and gene insertions. However, a number of design considerations should be taken into account to ensure maximum gene targeting efficiency and specificity. This is especially true when engineering human embryonic stem or induced pluripotent stem cells (iPSCs), which are more difficult to transfect and less resilient to DNA damage than immortalized tumor cell lines. Here, we describe a protocol for easily engineering genetic changes in human iPSCs, through which we typically achieve targeting efficiencies between 1% and 10% without any subsequent selection steps. Since this protocol only uses the simple transient transfection of plasmids and/or single-stranded oligonucleotides, most labs will easily be able to perform it. We also describe strategies for identifying, cloning, and genotyping successfully edited cells, and how to design the optimal sgRNA target sites and donor vectors. Finally, we discuss alternative methods for gene editing including viral delivery vectors, Cas9 nickases, and orthogonal Cas9 systems.

Entities:  

Keywords:  CRISPR; Cas9 nuclease; Gene targeting; Human genome engineering; Induced pluripotent stem cells; Transfection

Mesh:

Substances:

Year:  2014        PMID: 25398338      PMCID: PMC4408990          DOI: 10.1016/B978-0-12-801185-0.00006-4

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  53 in total

1.  Misleading gene conversion frequencies due to a PCR artifact using small fragment homologous replacement.

Authors:  David De Semir; Josep M Aran
Journal:  Oligonucleotides       Date:  2003

2.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

3.  Optimized production and concentration of lentiviral vectors containing large inserts.

Authors:  Nadya al Yacoub; Malgorzata Romanowska; Natalie Haritonova; John Foerster
Journal:  J Gene Med       Date:  2007-07       Impact factor: 4.565

4.  Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells.

Authors:  Xuebing Wu; David A Scott; Andrea J Kriz; Anthony C Chiu; Patrick D Hsu; Daniel B Dadon; Albert W Cheng; Alexandro E Trevino; Silvana Konermann; Sidi Chen; Rudolf Jaenisch; Feng Zhang; Phillip A Sharp
Journal:  Nat Biotechnol       Date:  2014-04-20       Impact factor: 54.908

5.  Zinc-finger nuclease-driven targeted integration into mammalian genomes using donors with limited chromosomal homology.

Authors:  Salvatore J Orlando; Yolanda Santiago; Russell C DeKelver; Yevgeniy Freyvert; Elizabeth A Boydston; Erica A Moehle; Vivian M Choi; Sunita M Gopalan; Jacqueline F Lou; James Li; Jeffrey C Miller; Michael C Holmes; Philip D Gregory; Fyodor D Urnov; Gregory J Cost
Journal:  Nucleic Acids Res       Date:  2010-06-08       Impact factor: 16.971

6.  Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly.

Authors:  Hye Joo Kim; Hyung Joo Lee; Hyojin Kim; Seung Woo Cho; Jin-Soo Kim
Journal:  Genome Res       Date:  2009-05-21       Impact factor: 9.043

7.  Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs.

Authors:  Qiurong Ding; Stephanie N Regan; Yulei Xia; Leoníe A Oostrom; Chad A Cowan; Kiran Musunuru
Journal:  Cell Stem Cell       Date:  2013-04-04       Impact factor: 24.633

8.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.

Authors:  Prashant Mali; John Aach; P Benjamin Stranges; Kevin M Esvelt; Mark Moosburner; Sriram Kosuri; Luhan Yang; George M Church
Journal:  Nat Biotechnol       Date:  2013-08-01       Impact factor: 54.908

9.  Improving CRISPR-Cas nuclease specificity using truncated guide RNAs.

Authors:  Yanfang Fu; Jeffry D Sander; Deepak Reyon; Vincent M Cascio; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-01-26       Impact factor: 54.908

10.  Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells.

Authors:  Ignazio Maggio; Maarten Holkers; Jin Liu; Josephine M Janssen; Xiaoyu Chen; Manuel A F V Gonçalves
Journal:  Sci Rep       Date:  2014-05-29       Impact factor: 4.379

View more
  44 in total

Review 1.  Genetic manipulation of secondary metabolite biosynthesis for improved production in Streptomyces and other actinomycetes.

Authors:  Richard H Baltz
Journal:  J Ind Microbiol Biotechnol       Date:  2015-09-12       Impact factor: 3.346

2.  Efficient CRISPR-Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus.

Authors:  Florian T Merkle; Werner M Neuhausser; David Santos; Eivind Valen; James A Gagnon; Kristi Maas; Jackson Sandoe; Alexander F Schier; Kevin Eggan
Journal:  Cell Rep       Date:  2015-04-30       Impact factor: 9.423

3.  CRISPR-Cas9-Based Genome Editing of Human Induced Pluripotent Stem Cells.

Authors:  Joseph C Giacalone; Tasneem P Sharma; Erin R Burnight; John F Fingert; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Curr Protoc Stem Cell Biol       Date:  2018-02-28

Review 4.  CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.

Authors:  Erin R Burnight; Joseph C Giacalone; Jessica A Cooke; Jessica R Thompson; Laura R Bohrer; Kathleen R Chirco; Arlene V Drack; John H Fingert; Kristan S Worthington; Luke A Wiley; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Prog Retin Eye Res       Date:  2018-03-22       Impact factor: 21.198

Review 5.  Brain Organoids as Tools for Modeling Human Neurodevelopmental Disorders.

Authors:  Jason W Adams; Fernanda R Cugola; Alysson R Muotri
Journal:  Physiology (Bethesda)       Date:  2019-09-01

6.  CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells.

Authors:  Joanna Jacków; Zongyou Guo; Corey Hansen; Hasan E Abaci; Yanne S Doucet; Jung U Shin; Ryota Hayashi; Dominick DeLorenzo; Yudai Kabata; Satoru Shinkuma; Julio C Salas-Alanis; Angela M Christiano
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-09       Impact factor: 11.205

7.  The necessity for in vivo functional analysis in human medical genetics.

Authors:  Anita M Quintana
Journal:  Med Res Arch       Date:  2015-11

Review 8.  Modeling Psychiatric Disorder Biology with Stem Cells.

Authors:  Debamitra Das; Kyra Feuer; Marah Wahbeh; Dimitrios Avramopoulos
Journal:  Curr Psychiatry Rep       Date:  2020-04-21       Impact factor: 5.285

9.  Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived iPSCs Using CRISPR/Cas9.

Authors:  Methichit Wattanapanitch
Journal:  Methods Mol Biol       Date:  2021

Review 10.  Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells.

Authors:  Alison E Mungenast; Sandra Siegert; Li-Huei Tsai
Journal:  Mol Cell Neurosci       Date:  2015-12-04       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.